Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Editorial fellow Dr Ariel Wampler describes what few know about material and device regulation, and Dr Adriane Fugh-Berman explains why we should ask more questions about device representatives’ intraoperative roles during implantations.
Jeffrey Bedard joins Ethics Talk to discuss his article: "What Should Patients Be Told About Device Representatives’ Roles at the Point of Surgical Care?"
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
COVID-19 underscores historical precedent for fear-driven responses that disregard autonomy among persons with low income who are also persons of color.
AMA J Ethics. 2021;23(11):E840-846. doi:
10.1001/amajethics.2021.840.
Clinicians and police are positioned to help persons experiencing homelessness, but little has been said about how their best impulses to serve could most productively overlap.
AMA J Ethics. 2021;23(11):E881-886. doi:
10.1001/amajethics.2021.881.
Neurophysiological sequelae of childhood trauma can express later in the lives of patients experiencing homelessness, especially during informed consent.
AMA J Ethics. 2021;23(11):E847-851. doi:
10.1001/amajethics.2021.847.